Tirzepatide: Difference between revisions
No edit summary |
(Add References section) |
||
| Line 6: | Line 6: | ||
*Vomiting | *Vomiting | ||
*Abdominal pain | *Abdominal pain | ||
==References== | |||
<references/> | |||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
Latest revision as of 09:15, 22 March 2026
Tirzepatide is a dual GIP and GLP-1 agonist approved for the treatment of type 2 diabetes and also used off-label for obesity treatment
Side Effects
- Pancreatitis
- Nausea
- Vomiting
- Abdominal pain